Are BPC-157 and TB-500 still legal after the April 2026 reclassification?
The regulatory picture changed in April 2026. On April 15, 2026, US regulators announced that 12 peptides - including BPC-157, TB-500, Semax, Epitalon, Melanotan II, and injectable GHK-Cu - would be removed from the Category 2 list that had previously restricted them. That change took effect April 23, 2026. Big caveat: removed from Category 2 is NOT the same as approved. The formal review for whether 503A pharmacies can legally compound these is scheduled for July 23-24, 2026. Until that review concludes, the access path is: licensed physician writes a prescription, licensed 503A compounding pharmacy fills it.
- April 15, 2026 announcement: 12 peptides removed from Category 2, effective April 23, 2026
- Peptides affected: BPC-157, TB-500, Semax, Epitalon, Melanotan II, GHK-Cu (injectable), KPV, MOTS-C, LL-37, DiHexa, DSIP (Emideltide), PEG-MGF
- July 23-24, 2026 PCAC meeting reviews 503A Bulk Drug Substances List additions: BPC-157 (free base and acetate), KPV, TB-500, MOTs-C on July 23; Emideltide (DSIP), Semax, Epitalon on July 24
- Separate track: Melanotan II, GHK-Cu injectable, LL-37, PEG-MGF, DiHexa - review expected before February 2027
- Removal from Category 2 does NOT mean: peptides are approved for human use, can be purchased without a prescription, gray market sales are legal, or 503A pharmacies can automatically begin compounding them
Your guided peptide companion.
PRTCL walks beginners through their first peptide with confidence - guided reconstitution, dose calculation, vial tracking, and answers to questions like this one. Built for first-timers, useful for everyone.
- · Guided walkthrough for your first dose
- · Dose calculator that does the math for you
- · Vial inventory and dose log tracking
- · Library of physician-vetted protocols
Free to start.